1048
U N I T 1 1
Genitourinary and Reproductive Function
30. Falcone T, Lebovic DI. Clinical management of endometriosis.
Obstet Gynecol.
2011;118:691–705.
31. Bakkum-Gamez J, Gonzalez-Bosquet J, Laack NN, et al. Current
issues in the management of endometrial cancer.
Mayo Clin Proc.
2008;83(1):97–112.
32. Wright JD, Mendel NIB, Schauli J, et al. Contemporary
management of endometrial cancer.
Lancet.
2012;379:1352–1360.
33. Buchanan EM, Weinstein LC, Hillson C. Endometrial cancer.
Am
Fam Physician.
2009;80(10):1075–1989.
34. DiCristofano A, Ellenson LH. Endometrial carcinoma.
Annu Rev
Pathol Mech Dis.
2007;2:57–85.
35. Evans P, Brunsell S. Uterine fibroid tumors: diagnosis and
treatment.
Am Fam Physician.
2007;75:1503–1508.
36. Lentz GM. Anatomic defects of the abdominal wall and pelvic
floor. In: Lentz GM, Lobo RA, Gershenson DM, et al., eds.
Comprehensive Gynecology
. 6th ed. Philadelphia, PA: Elsevier
Mosby; 2012:453.e3–477.e3.
37. Azziz R. Diagnostic criteria for polycystic ovary syndrome: a
reappraisal.
Fertil Steril.
2005;83:1343–1346.
38. Goodarzi MO, Dumesic DA, Chazenbath G, et al. (2013).
Polycystic ovary syndrome: etiology, pathogenesis and diagnosis.
Nat Rev Endocrinol.
7:219–231.
39. Ehrmann DA. Polycystic ovary syndrome.
N Engl J Med.
2005;352:1223–1236.
40. Salmi DJ, Zisser HC, Jovanovic L. Screening for and treatment of
polycystic ovary syndrome in teenagers: a mini review.
Exp Biol
Med.
2004;229:369–377.
41. Roett MA, Evans D. Ovarian cancer.
Am Fam Physician.
2009;80(6):609–616.
42. Chobanian N, Dietrich CS. Ovarian cancer.
Surg Clin North Am.
2008;88:285–299.
43. Vo C, Carney ME. Ovarian cancer hormonal and environmental
risk effect.
Obstet Gynecol Clin North Am.
2007;34:687–700.
44. Goff BA, Mandel LS, Drescher CW, et al. Development of an
ovarian cancer symptom index: possibilities for earlier detection.
Cancer.
2006;109:221–227.
45. Casablanca Y. Management of dysfunctional uterine bleeding.
Obstet Gynecol Clin North Am.
2008;35:219–234.
46. Practice Committee of the American Society for Reproductive
Medicine. Current evaluation of amenorrhea.
Fertil Steril.
2006;86(suppl 4):S148–S155.
47. Morrow C, Naumburg E. Dysmenorrhea.
Prim Care Clin Office
Pract.
2009;36:10–32.
48. Minkin MJ, Moore AE. Identifying and managing premenstrual
disorders: putting strategies into practice.
Clin Adv.
2006;(suppl):4–15.
49. Dickerson VM. Premenstrual syndrome and premenstrual
dysphoric disorder: individualizing therapy.
Fem Patient.
2007;32(1):38–46.
50. Biggs WS, Demuth RH. Premenstrual syndrome and
premenstrual dysphoric disorder.
Am Fam Physician.
2011;84(8):918–924.
51. Braverman PK. Premenstrual syndrome and premenstrual
dysphoric disorder.
J Pediatr Adolesc Gynecol.
2007:203–212.
52. Rees M. Management of the menopause: integrated health-
care pathway for the menopausal woman.
Menopause Int.
2011;17(2):50–54.
53. Lyons J. Advice given to women undergoing gynaecological
surgery in relation to menopause, symptoms and hormone
replacement therapy: could and should we improve the service
we provide?
Menopause Int.
2011;17(2):59–62.
54. North American Menopause Society. The 2012 Hormone
Therapy Position Statement of the North American Menopause
Society.
Menopause.
2012;19(3):257–271.
55. Rossouw JE, Manson JE, Kaunitz AM. Lessons learned from the
Women’s Health Initiative trials of menopausal hormone therapy.
Obstet Gynecol.
2013;121(1):172–176.
56. Gadducci A; Guerrieri ME, Genazzani AR. Benign breast
diseases, contraception and hormone replacement therapy.
Minerva Ginecol.
2012;64(1):67–74.
57. Lester SC. The breast. In: Kumar V, Abbas AK, Fausto N, et al.,
eds.
Robbins and Cotran Pathologic Basis of Disease
. 8th ed.
Philadelphia, PA: Saunders Elsevier; 2010:1065–1095.
58. Mulligan AM, O’Malley FP. The breast. In: Rubin R, Strayer
DS, eds.
Rubin’s Pathology: Clinicopathologic Foundations of
Medicine
. 6th ed. Philadelphia, PA: Wolters Kluwer Health/
Lippincott Williams & Wilkins; 2012:923–945.
59. Barbieri, R. What is the gynecologist’s role in the care of BRCA
previvors?
OBG Manage.
2013;25(9):10–14.
60. Hamilton R. Genetics: breast cancer as an exemplar.
Nurs Clin
North Am.
2009;44(3):327–338.
61. Maughan KL, Lutterbie MA, Ham PS. Treatment of breast
cancer.
Am Fam Physician.
2009;81(1):1339–1346.
62. American Cancer Society. Detailed guide: breast cancer. 2013.
Available at:
.
Accessed July 10, 2013.
63. Denkert, C, Huober J, Loibl S, et al. HER2 and ESR1 mRNA
expression levels and response to neoadjuvant trastuzumab plus
chemotherapy in patients with primary breast cancer.
Breast
Cancer Res.
2013;15(1):R11.
64. Lønning PE. The potency and clinical efficacy of aromatase
inhibitors across the breast cancer continuum.
Ann Oncol.
2011;22(3):503–514.
Porth Essentials Resources
Explore these additional resources to enhance learning
for this chapter:
•
NCLEX-Style Questions and Other Resources
on
,
•
Study Guide for Essentials of Pathophysiology
•
Adaptive Learning | Powered by PrepU,
prepu
